Comparison
5q14 3 Microdeletion Syndrome C4304529 vs 2 Hydroxyglutarate Aciduria C5139239
Clinical comparison between 5q14 3 Microdeletion Syndrome and 2 Hydroxyglutarate Aciduria for differential diagnosis and treatment planning.
5q14 3 Microdeletion Syndrome C4304529
A rare genetic condition involving deletion of a small region on chromosome 5, affecting brain development and often causing seizures and developmental issues.
2 Hydroxyglutarate Aciduria C5139239
A metabolic disorder causing buildup of 2-hydroxyglutaric acid. It may affect the brain and nervous system. Management includes supportive therapies and monitoring for complications.
6 comparison axes
Onset
5q14 3 Microdeletion Syndrome C4304529
Variable
2 Hydroxyglutarate Aciduria C5139239
0-10
Onset patterns differ
Severity
5q14 3 Microdeletion Syndrome C4304529
severe
2 Hydroxyglutarate Aciduria C5139239
moderate
Different severity levels
Chronic
5q14 3 Microdeletion Syndrome C4304529
Chronic
2 Hydroxyglutarate Aciduria C5139239
Chronic
Differing course
Communicable
5q14 3 Microdeletion Syndrome C4304529
No
2 Hydroxyglutarate Aciduria C5139239
No
Different transmission
Body System
5q14 3 Microdeletion Syndrome C4304529
congenital
2 Hydroxyglutarate Aciduria C5139239
metabolic
Same/different system
Category
5q14 3 Microdeletion Syndrome C4304529
genetic
2 Hydroxyglutarate Aciduria C5139239
metabolic
Different category
Bottom line
5q14-3-microdeletion-syndrome-C4304529 and 2-hydroxyglutarate-aciduria-C5139239 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 5q14 3 Microdeletion Syndrome C4304529 | 2 Hydroxyglutarate Aciduria C5139239 | Discriminating power |
|---|---|---|---|
| Developmental problems | Often linked to impaired brain development from the deletion. | May occur if the metabolic disorder affects the nervous system. | Moderate |
| Seizures | Described as a frequent feature in the source. | Not established as defining from the supplied description. | Moderate |
| Metabolite accumulation | Not primarily characterized by organic-acid buildup. | Defined by accumulation of 2-hydroxyglutaric acid. | High |
When to favor each condition
Choose 5q14 3 Microdeletion Syndrome C4304529 when
A confirmed 5q14.3 microdeletion is identified
The genetic finding directly matches the named syndrome.
High
Severe congenital neurodevelopmental features predominate
The source classifies this condition as congenital, genetic, and severe.
Moderate
Onset timing is variable rather than clearly childhood-limited
The supplied onset axis is variable for the deletion syndrome.
Low
Choose 2 Hydroxyglutarate Aciduria C5139239 when
2-hydroxyglutaric acid accumulation is documented
This metabolic finding supports aciduria, pending clinical confirmation.
High
Symptoms begin from birth through age 10
The supplied onset range is 0–10 years.
Moderate
A metabolic explanation fits better than a chromosomal deletion
The source categorizes it as metabolic with moderate severity.
Moderate
How key tests differ
| Test | 5q14 3 Microdeletion Syndrome C4304529 | 2 Hydroxyglutarate Aciduria C5139239 | Interpretation |
|---|---|---|---|
| Chromosomal microarray | May detect a small 5q14.3 deletion. | Does not establish 2-hydroxyglutarate aciduria. | A deletion supports the left condition but does not exclude unrelated metabolic disease. |
| Urine organic acid analysis | No defining metabolite pattern is supplied. | May show elevated 2-hydroxyglutarate; no cutoff is supplied. | An abnormal result is not automatically a diagnosis and needs clinician review. |
| Neurologic assessment | May document developmental impairment or seizures. | May show nervous-system involvement when present. | Overlap is possible, so assessment alone cannot reliably separate them. |
Prognosis comparison
5q14 3 Microdeletion Syndrome C4304529
- Outcome
- Labeled severe and chronic, but individual prognosis is not established.
- Factors
- Brain-development effects, seizures, and developmental issues.
2 Hydroxyglutarate Aciduria C5139239
- Outcome
- Labeled moderate and chronic, with variable and unquantified outcomes.
- Factors
- Extent of acid accumulation and nervous-system involvement.
Time frame: Long-term; left onset is variable and right onset is listed as 0–10 years.
Etiology, severity, complications, and supportive care; no mortality data are supplied.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic complications | Seizures and developmental issues are described. Brain and nervous-system effects may occur. Frequencies and exact manifestations are not established here. |
| Developmental disability | Often central and labeled severe in the source. Possible, with overall severity labeled moderate. Individual outcomes require clinical assessment. |
| Long-term care needs | Chronic congenital condition requiring follow-up. Chronic metabolic condition requiring monitoring. Neither is communicable; treatment doses are not supplied. |
Patient education highlights
- HighResult versus diagnosis
A genetic or metabolite abnormality needs specialist interpretation before either diagnosis is assigned.
- HighTransmission
The supplied data indicate that neither condition is communicable.
- MediumFollow-up
Both may require long-term developmental and neurologic monitoring; specific treatments are not established here.